Neuronetics, Inc. (NASDAQ:STIM) Short Interest Down 37.3% in November

Neuronetics, Inc. (NASDAQ:STIM) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 607,300 shares, a decrease of 37.3% from the November 15th total of 969,100 shares. Based on an average daily volume of 452,500 shares, the short-interest ratio is currently 1.3 days.

Neuronetics Price Performance

Shares of STIM stock opened at $1.12 on Friday. Neuronetics has a 1 year low of $0.52 and a 1 year high of $5.07. The firm’s 50 day moving average is $0.98 and its 200-day moving average is $1.28. The firm has a market capitalization of $33.99 million, a price-to-earnings ratio of -0.91 and a beta of 2.25. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Hedge Funds Weigh In On Neuronetics

A number of large investors have recently modified their holdings of STIM. Assenagon Asset Management S.A. raised its stake in shares of Neuronetics by 63.0% during the second quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock worth $244,000 after buying an additional 52,450 shares during the last quarter. Legato Capital Management LLC bought a new stake in shares of Neuronetics during the second quarter worth $44,000. Acadian Asset Management LLC increased its position in shares of Neuronetics by 23.7% during the second quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock worth $587,000 after acquiring an additional 62,628 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its position in shares of Neuronetics by 97.1% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock worth $173,000 after acquiring an additional 47,228 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Neuronetics by 124.5% during the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock worth $580,000 after acquiring an additional 178,700 shares in the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.